Trial · NCT07463820
A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)
NCT07463820, Phase 2, Not yet recruiting, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial). Trials, record NCT07463820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07463820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)
- NCT number
- NCT07463820
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 270 participants, estimated
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Emavusertib, Epoetin Alfa, Luspatercept
- First posted
- 2026-03-11
- Last updated
- 2026-09-22
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Erythroid response rate | At 24 weeks | Defined by the total number of patients with hematologic improvement-erythroid (HI-E) response divided by the total number of randomized patients in each arm. The comparison of the HI-E rate will be done using a Cochran-Mantel-Haenszel test stratified for the stratification factors at randomization based on the intent-to-treat population. The difference in the response rates and the corresponding one-sided 90% confidence limit will be calculated. |
| Secondary | Transfusion free survival | Up to 2 years | Defined as from achieving transfusion independence to the first day of transfusions after becoming transfusion dependent as defined by International Working Group (IWG) 2018 criteria for those who are transfusion dependent at enrollment or time to first day of transfusions as defined by IWG 2018 criteria for those nor transfusion dependent at enrollment. |
| Secondary | Duration of erythroid response | From meeting criteria for HI-E response to progression or relapse as defined by IWG 2018 criteria, up to 2 years | |
| Secondary | Tri-lineage response | Up to 2 years | Tri-lineage response involves erythroid, neutrophil, and platelet response per IWG 2018 criteria. |
| Secondary | Bi-lineage response | Up to 2 years | Any two of the responses for erythroid, neutrophil, and platelet response per IWG 2018 criteria. |
| Secondary | Incidence of adverse events | From the time of first treatment, up to 2 years | |
| Secondary | Overall survival | From enrollment to death from any cause, up to 2 years | |
| Secondary | Overall leukemia free survival | From enrollment to initial diagnosis of acute leukemia or death from any cause, up to 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA180863 | Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network | Dancey, Janet Ellen | QUEEN'S UNIVERSITY AT KINGSTON | NATIONAL CANCER INSTITUTE | 2014 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07463820
GET https://conductscience.org/api/trials/v1/NCT07463820/registered